Literature DB >> 10925356

u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.

D Tavian1, G De Petro, A Benetti, N Portolani, S M Giulini, S Barlati.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) is one of the most important humoral mediators of liver regeneration. It is potentially related to molecular mechanisms of hepatocarcinogenesis via a paracrine system involving its cellular receptor, c-met. In this study, the expression patterns of HGF and c-met were evidenced by multiplex RT-PCR in different specimens of human hepatic tissues (n = 71). A significant increase of c-met mRNA expression was detected in hepatitis (P = 0.001), cirrhosis (P = 0.006), and hepatocellular carcinoma (HCC) tissue (P = 0.003) compared with normal parenchyma and steatosis. HGF mRNA expression was significantly higher only in hepatitis (P = 0.01). Over-expression of c-met mRNA and under-expression of HGF mRNA were detected in the HCCs compared with the corresponding peri-tumoral tissues. Neither HGF nor c-met expression was related to age, sex, tumor size, grading, presence of pseudocapsula, and proliferative activity of the malignant hepatocytes. A significant inverse correlation was found between c-met mRNA expression level and survival (in months) of patients (P = 0.007), as previously shown for urokinase-type plasminogen activator (u-PA) mRNA (P = 0.027). In addition, c-met mRNA expression was strictly associated with u-PA mRNA level in HCC samples (P = 0.001). These data show that a loss of balance concerning HGF, c-met, and u-PA mRNA expression occurs during hepatocarcinogenesis. Particularly, up-regulation of c-met and u-PA mRNA transcription appears to be coordinately regulated, and their levels of expression are inversely correlated with survival; they must therefore play an important role in the development and progression of human HCC and may also be relevant prognostic markers. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10925356

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Association of the human astrocyte elevated gene-1 promoter variants with susceptibility to hepatocellular carcinoma.

Authors:  Gholamreza Motalleb; Naghmeh Gholipour; Nader Mansour Samaei
Journal:  Med Oncol       Date:  2014-03-22       Impact factor: 3.064

2.  Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma.

Authors:  Scott M Thompson; Danielle E Jondal; Kim A Butters; Bruce E Knudsen; Jill L Anderson; Matthew P Stokes; Xiaoying Jia; Joseph P Grande; Lewis R Roberts; Matthew R Callstrom; David A Woodrum
Journal:  Int J Hyperthermia       Date:  2017-11-06       Impact factor: 3.914

Review 3.  Molecular targeted therapy for hepatocellular carcinoma: current and future.

Authors:  Jung Woo Shin; Young-Hwa Chung
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

Review 4.  c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Authors:  Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.

Authors:  Susie A Lee; Sara Ladu; Matthias Evert; Frank Dombrowski; Valentina De Murtas; Xin Chen; Diego F Calvisi
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 6.  Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis.

Authors:  Yeliz Yılmaz; Ayşim Güneş; Hande Topel; Neşe Atabey
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 7.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

Review 8.  Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.

Authors:  Gan-Lu Deng; Shan Zeng; Hong Shen
Journal:  World J Hepatol       Date:  2015-04-18

9.  Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

Authors:  Zheng Wang; You-Bing Ruan; Yang Guan; Sheng-Hong Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

10.  The Met protooncogene is a transcriptional target of NF kappaB: implications for cell survival.

Authors:  James Y Dai; Marie C DeFrances; Chunbin Zou; Carla J Johnson; Reza Zarnegar
Journal:  J Cell Biochem       Date:  2009-08-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.